Sanofi (SNY) Operating Leases (2019 - 2025)

Sanofi has disclosed Operating Leases across 7 years of filings, most recently posting $2.0 billion for Q4 2025.

• Operating Leases for Q4 2025 came in at $2.0 billion, up 15.16% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 billion (up 15.16% YoY), and the FY2025 annual result was $2.0 billion, up 15.16% from the prior year.
• Operating Leases came in at $2.0 billion for Q4 2025 at Sanofi, up from $1.7 billion in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.2 billion in Q4 2023 to a low of $1.5 billion in Q2 2021.
• The 5-year median for Operating Leases is $2.0 billion (2022), against an average of $1.9 billion.
• Across the five-year window, Operating Leases soared 43.39% in 2021 and declined 19.52% in 2024, its largest moves.
• Sanofi's Operating Leases stood at $2.1 billion in 2021, then slipped by 7.66% to $1.9 billion in 2022, then gained by 12.44% to $2.2 billion in 2023, then declined by 19.52% to $1.8 billion in 2024, then grew by 15.16% to $2.0 billion in 2025.
• The last three Operating Leases figures came in at $2.0 billion (Q4 2025), $1.7 billion (Q2 2025), and $1.8 billion (Q4 2024), per Business Quant data.